[go: up one dir, main page]

FI20030393A0 - Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi - Google Patents

Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Info

Publication number
FI20030393A0
FI20030393A0 FI20030393A FI20030393A FI20030393A0 FI 20030393 A0 FI20030393 A0 FI 20030393A0 FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A0 FI20030393 A0 FI 20030393A0
Authority
FI
Finland
Prior art keywords
predicting
treat
compounds
course
methods
Prior art date
Application number
FI20030393A
Other languages
English (en)
Swedish (sv)
Other versions
FI20030393L (fi
FI20030393A7 (fi
Inventor
Pirkko Vihko
Veli Isomaa
Original Assignee
Molekyyliendokrinologian Tutki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molekyyliendokrinologian Tutki filed Critical Molekyyliendokrinologian Tutki
Priority to FI20030393A priority Critical patent/FI20030393A7/fi
Publication of FI20030393A0 publication Critical patent/FI20030393A0/fi
Priority to EP04720024A priority patent/EP1603571A2/en
Priority to PCT/FI2004/000145 priority patent/WO2004080271A2/en
Publication of FI20030393L publication Critical patent/FI20030393L/fi
Publication of FI20030393A7 publication Critical patent/FI20030393A7/fi
Priority to US11/225,095 priority patent/US20060057628A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI20030393A 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi FI20030393A7 (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
EP04720024A EP1603571A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
PCT/FI2004/000145 WO2004080271A2 (en) 2003-03-14 2004-03-12 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
US11/225,095 US20060057628A1 (en) 2003-03-14 2005-09-14 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Publications (3)

Publication Number Publication Date
FI20030393A0 true FI20030393A0 (fi) 2003-03-14
FI20030393L FI20030393L (fi) 2004-09-15
FI20030393A7 FI20030393A7 (fi) 2004-09-15

Family

ID=8565817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030393A FI20030393A7 (fi) 2003-03-14 2003-03-14 Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi

Country Status (4)

Country Link
US (1) US20060057628A1 (fi)
EP (1) EP1603571A2 (fi)
FI (1) FI20030393A7 (fi)
WO (1) WO2004080271A2 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US8088758B2 (en) 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
RU2409581C2 (ru) * 2004-12-13 2011-01-20 Зольвай Фармасьютиклз Гмбх НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ
ES2327240T3 (es) * 2004-12-13 2009-10-27 Solvay Pharmaceuticals Gmbh Nuevos derivados sustituidos de tiofempirimidinona en calidad de inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101884706B (zh) * 2010-07-01 2014-05-28 广州市花城制药厂 一种祛痰止咳颗粒的检测方法

Also Published As

Publication number Publication date
FI20030393L (fi) 2004-09-15
FI20030393A7 (fi) 2004-09-15
WO2004080271A2 (en) 2004-09-23
WO2004080271A3 (en) 2004-11-04
EP1603571A2 (en) 2005-12-14
US20060057628A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
EP1667680A4 (en) COMBINATION PROCEDURE FOR THE TREATMENT OF CANCER
EP1575580A4 (en) METHOD FOR TREATING CARCINOMA
IL258880A (en) Diarylhydantoin compounds
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
IL180601A0 (en) Methods and compositions for the detection of ovarian cancer
HUE048404T2 (hu) Claudin-18 elleni monoklonális antitestek rák kezelésére
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1677794A4 (en) METHODS OF TREATING DISORDERS
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
FI20021807L (fi) Menetelmä akryyliamidin muodostumisen estämiseksi tai vähentämiseksi elintarvikkeissa
FI20030771A7 (fi) Menetelmä toksisten syanobakteerien määrittämiseksi
DE602004032525D1 (de) Rstellungsverfahren dafür
EP1594433A4 (en) SENSITIZING A CANCER THERAPY
FI20030393A0 (fi) Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
EP1902068A4 (en) EGFR INHIBITORS AS PROMOTERS OF NEURITE GENERATION
DE602004026773D1 (de) Verfahrensherstellung von ethern
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT

Legal Events

Date Code Title Description
FD Application lapsed